Here’s Why You Shouldn’t Abandon GT Advanced Technologies Inc (GTAT)… Yet

Page 1 of 2

No matter how the bulls try to spin it, GT Advanced Technologies Inc (NASDAQ:GTAT)‘s  fourth-quarter and full-year 2012 earnings were ugly, plain and simple.

The numbers
For the quarter, revenue fell 33% from the year-ago period to $102.3 million, helping GTAT achieve an eye-popping net loss of $159.4 million.

GT Advanced Technologies Inc (NASDAQ:GTAT)Of course, it’s important to note those scary numbers incorporate nearly $162 million in one-time charges, including a nearly $72 million “write down of inventory and related charges” due to prevailing poor photovoltaic (PV) market conditions, $57 million “related to the impairment of goodwill related to the PV business,” and a $2.5 million hit from “certain sapphire materials assets acquired with the acquisition of the business which are now obsolete.” Ouch!

If we put these big charges aside, however, GT Advanced Technologies Inc (NASDAQ:GTAT) actually managed a slightly more respectable adjusted net loss of just $18.1 million. Interestingly enough, the folks at GTAT weren’t surprised in the least, with CEO Tom Gutierrez asserting:

Our Q4 results came in largely as expected as we continue to face challenging conditions in the solar and LED markets. We have taken steps to resize the business and manage our balance sheet and believe 2013 will be a year during which we continue to strengthen our foundation and further diversify the business.

As fellow fool Travis Hoium pointed out last week, while solar specialists including LDK Solar Co., Ltd (ADR) (NYSE:LDK) , Trina Solar Limited (ADR) (NYSE:TSL) , and Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE:YGE) have historically been some of GTAT’s largest solar equipment buyers in the past, few are currently in the financial position to make additional investments in the company’s latest HiCz technology. Indeed, as the solar industry has continued to crumble over the last two years, shares of LDK, Trina, and Yingli have fallen 78%, 77%, and 87%, respectively.

What’s more, even GTAT’s customers who do have cash to purchase new equipment have been kept on the sidelines as the result of unresolved international trade tensions in the solar sector. Even still, Guiterrez also mentioned during the conference call he sees evidence that their “largest customers’ access to government and commercial capital is likely to improve over the next several quarters.” Considering HiCz will help the likes of LDK, Trina, and Yingli even further decrease the cost and increase overall efficiency of solar cells going forward, its a safe bet GT Advanced Technologies Inc (NASDAQ:GTAT) remains nicely positioned to profit when market conditions finally improve.

For now, however, with the current oversupply helping to extend the deterioration of GTAT’s core business, its shares currently trade hands more than 80% below the all-time high mark set less than two years ago. It’s reassuring, then, that the folks at GTAT have no delusions that market conditions will improve in the near future. As a result, the company plans to delay any significant expenditures related to market introduction of their HiCz product until 2014, at which time they believe market demand will finally drive adoption.

The potential
For its part, GT Advanced Technologies Inc (NASDAQ:GTAT) still isn’t content to rest on its laurels. To the contrary, the company is working diligently to continue diversifying its business away from solar and further toward the growing sapphire segment. Sure enough, it expects more than half its 2013 revenue to come from its sapphire business, with the bulk of that arriving during the second half of the year. Fortunately, these expectations are bolstered by the fact that $716.5 million of GTAT’s $1.25 billion backlog at the end of 2012 was attributable to the sapphire segment, with around 2/3 driven by LED and industrial solutions and the remaining third to come from emerging applications including potential low-volume smartphone and camera lens adoption.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!